Arcus Biosciences (RCUS) Equity Average (2018 - 2025)
Historic Equity Average for Arcus Biosciences (RCUS) over the last 8 years, with Q3 2025 value amounting to $492.5 million.
- Arcus Biosciences' Equity Average fell 1791.67% to $492.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $492.5 million, marking a year-over-year decrease of 1791.67%. This contributed to the annual value of $473.5 million for FY2024, which is 1537.09% down from last year.
- Per Arcus Biosciences' latest filing, its Equity Average stood at $492.5 million for Q3 2025, which was down 1791.67% from $540.0 million recorded in Q2 2025.
- Arcus Biosciences' Equity Average's 5-year high stood at $819.5 million during Q1 2022, with a 5-year trough of $491.0 million in Q4 2023.
- In the last 5 years, Arcus Biosciences' Equity Average had a median value of $584.5 million in 2024 and averaged $612.8 million.
- In the last 5 years, Arcus Biosciences' Equity Average surged by 28330.73% in 2021 and then tumbled by 2758.11% in 2023.
- Quarter analysis of 5 years shows Arcus Biosciences' Equity Average stood at $692.3 million in 2021, then fell by 2.07% to $678.0 million in 2022, then decreased by 27.58% to $491.0 million in 2023, then rose by 6.92% to $525.0 million in 2024, then dropped by 6.19% to $492.5 million in 2025.
- Its Equity Average stands at $492.5 million for Q3 2025, versus $540.0 million for Q2 2025 and $508.0 million for Q1 2025.